Cargando…
Design of high-order antibiotic combinations against M. tuberculosis by ranking and exclusion
Combinations of more than two drugs are routinely used for the treatment of pathogens and tumors. High-order combinations may be chosen due to their non-overlapping resistance mechanisms or for favorable drug interactions. Synergistic/antagonistic interactions occur when the combination has a higher...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6695482/ https://www.ncbi.nlm.nih.gov/pubmed/31417151 http://dx.doi.org/10.1038/s41598-019-48410-y |
_version_ | 1783444049179443200 |
---|---|
author | Yilancioglu, Kaan Cokol, Murat |
author_facet | Yilancioglu, Kaan Cokol, Murat |
author_sort | Yilancioglu, Kaan |
collection | PubMed |
description | Combinations of more than two drugs are routinely used for the treatment of pathogens and tumors. High-order combinations may be chosen due to their non-overlapping resistance mechanisms or for favorable drug interactions. Synergistic/antagonistic interactions occur when the combination has a higher/lower effect than the sum of individual drug effects. The standard treatment of Mycobacterium tuberculosis (Mtb) is an additive cocktail of three drugs which have different targets. Herein, we experimentally measured all 190 pairwise interactions among 20 antibiotics against Mtb growth. We used the pairwise interaction data to rank all possible high-order combinations by strength of synergy/antagonism. We used drug interaction profile correlation as a proxy for drug similarity to establish exclusion criteria for ideal combination therapies. Using this ranking and exclusion design (R/ED) framework, we modeled ways to improve the standard 3-drug combination with the addition of new drugs. We applied this framework to find the best 4-drug combinations against drug-resistant Mtb by adding new exclusion criteria to R/ED. Finally, we modeled alternating 2-order combinations as a cycling treatment and found optimized regimens significantly reduced the overall effective dose. R/ED provides an adaptable framework for the design of high-order drug combinations against any pathogen or tumor. |
format | Online Article Text |
id | pubmed-6695482 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-66954822019-08-19 Design of high-order antibiotic combinations against M. tuberculosis by ranking and exclusion Yilancioglu, Kaan Cokol, Murat Sci Rep Article Combinations of more than two drugs are routinely used for the treatment of pathogens and tumors. High-order combinations may be chosen due to their non-overlapping resistance mechanisms or for favorable drug interactions. Synergistic/antagonistic interactions occur when the combination has a higher/lower effect than the sum of individual drug effects. The standard treatment of Mycobacterium tuberculosis (Mtb) is an additive cocktail of three drugs which have different targets. Herein, we experimentally measured all 190 pairwise interactions among 20 antibiotics against Mtb growth. We used the pairwise interaction data to rank all possible high-order combinations by strength of synergy/antagonism. We used drug interaction profile correlation as a proxy for drug similarity to establish exclusion criteria for ideal combination therapies. Using this ranking and exclusion design (R/ED) framework, we modeled ways to improve the standard 3-drug combination with the addition of new drugs. We applied this framework to find the best 4-drug combinations against drug-resistant Mtb by adding new exclusion criteria to R/ED. Finally, we modeled alternating 2-order combinations as a cycling treatment and found optimized regimens significantly reduced the overall effective dose. R/ED provides an adaptable framework for the design of high-order drug combinations against any pathogen or tumor. Nature Publishing Group UK 2019-08-15 /pmc/articles/PMC6695482/ /pubmed/31417151 http://dx.doi.org/10.1038/s41598-019-48410-y Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Yilancioglu, Kaan Cokol, Murat Design of high-order antibiotic combinations against M. tuberculosis by ranking and exclusion |
title | Design of high-order antibiotic combinations against M. tuberculosis by ranking and exclusion |
title_full | Design of high-order antibiotic combinations against M. tuberculosis by ranking and exclusion |
title_fullStr | Design of high-order antibiotic combinations against M. tuberculosis by ranking and exclusion |
title_full_unstemmed | Design of high-order antibiotic combinations against M. tuberculosis by ranking and exclusion |
title_short | Design of high-order antibiotic combinations against M. tuberculosis by ranking and exclusion |
title_sort | design of high-order antibiotic combinations against m. tuberculosis by ranking and exclusion |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6695482/ https://www.ncbi.nlm.nih.gov/pubmed/31417151 http://dx.doi.org/10.1038/s41598-019-48410-y |
work_keys_str_mv | AT yilancioglukaan designofhighorderantibioticcombinationsagainstmtuberculosisbyrankingandexclusion AT cokolmurat designofhighorderantibioticcombinationsagainstmtuberculosisbyrankingandexclusion |